Trial reportEuropean journal of nuclear medicine and molecular imaging2017
Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib.
Trial report in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Clinical utility and future directions of FDG-PET in rectal cancer management.Annals of nuclear medicine · 2026Review
- Predictive value ofBMC cancer · 2025Article
- Imaging glucose metabolism to reveal tumor progression.Frontiers in physiology · 2023Review
- Influence of Semiquantitative [Pharmaceuticals (Basel, Switzerland) · 2022Article
- Article
- Article
- Prognostic Value of Quantitative [Diagnostics (Basel, Switzerland) · 2021Article
- Radiomics Features ofCancers · 2021Article
- Glycolysis Changes the Microenvironment and Therapeutic Response Under the Driver of Gene Mutation in Esophageal Adenocarcinoma.Frontiers in genetics · 2021Article
- Total Lesion Glycolysis Estimated by a Radiomics Model From CT Image Alone.Frontiers in oncology · 2021Article
- Predictive Value of Metabolic Parameters Derived FromFrontiers in immunology · 2021Article
- Combined quality and dose-volume histograms for assessing the predictive value ofEJNMMI physics · 2020Article
- 3'-Deoxy-3'-European journal of nuclear medicine and molecular imaging · 2019Article
- Radiomics analysis of pre-treatment [European journal of nuclear medicine and molecular imaging · 2018Article
- Article
- Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report.Medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study was performed to evaluate whether fluorine-18 fluorodeoxyglucose positron-emission tomography/computed tomography (FDG PET/CT) could predict treatment outcome of regorafenib in metastatic colorectal cancer (mCRC).
methodsPreviously treated refractory mCRC patients were enrolled into a prospective biomarker study of regorafenib. For this sub-study, the results of FDG PET/CT scans at baseline and after two cycles of treatment were analyzed. Various metabolic parameters obtained from PET images were analyzed in relation to treatment outcome.
resultsA total of 40 patients were evaluable for PET image analysis. Among various PET parameters, total lesion glycolysis (TLG) measured in the same target lesions for RECIST 1.1 analysis were the most significant in predicting prognosis, with the lowest p-value observed in TLG calculated using the margin threshold of 40 % (TLG
conclusionMeasurement of TLG can predict treatment outcome of regorafenib in mCRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.